共 195 条
[1]
Colditz GA(1998)Relationship between estrogen levels, use of hormone replacement therapy, and Breast cancer JNCIJ Natl Cancer Inst Cancer Inst 90 814-823
[2]
Burstein HJ(2014)Adjuvant endocrine therapy for women with hormone receptor-Positive Breast cancer: American society of clinical oncology clinical practice guideline focused updateJ Clin Oncol 32 2255-2269
[3]
Temin S(2013)Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 24 vi7-23
[4]
Anderson H(2015)Mechanisms of aromatase inhibitor resistance Nat Rev Cancer 15 261-275
[5]
Buchholz TA(2014)Estrogen Response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estrogen-deprivation resistant mechanisms J Steroid Biochem Mol Biol 139 61-72
[6]
Davidson NE(2017)Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer J Steroid Biochem Mol Biol 167 115-254
[7]
Gelmon KE(2014)Targeting the PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer Cancer Treat Rev 40 862-871
[8]
Senkus E(2018)Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer Oncotarget 9 21468-21477
[9]
Kyriakides S(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-1936
[10]
Penault-Llorca F(2016)Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Med 375 1738-1748